Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last?

Alphatec ATEC shares ended the last trading session 19.7% higher at $10.58. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 9.3% loss over the past four weeks.

Alphatec scored a strong price increase on investors’ optimism surrounding the company’s solid second quarter of 2026 performance. The company posted earnings per share of 7 cents while revenues came in at $213.5 million in the second quarter. For full year 2026, the company continues to expect total revenue of approximately $882 million, following a second quarter characterized by strong case volume growth, continued surgeon adoption, expanding profitability and positive free cash flow generation.

This medical equipment and supplies holding company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +266.7%. Revenues are expected to be $224.28 million, up 14.1% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Alphatec, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATEC going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Alphatec belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, ClearPoint Neuro, Inc. CLPT, closed the last trading session 1.8% higher at $13.72. Over the past month, CLPT has returned -12.6%.

ClearPoint Neuro's consensus EPS estimate for the upcoming report has changed +11.5% over the past month to -$0.27. Compared to the company's year-ago EPS, this represents a change of -28.6%. ClearPoint Neuro currently boasts a Zacks Rank of #4 (Sell).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research